ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Committee Discusses Cap On Center Grants, New Guidelines

October 18, 1991

NCI Developing Plan To Replace Research Contracts At Academic Institutions With “Program Grants”

February 22, 1974

CCRAC Calls for New Comp Center, Community Hospital Core Grants For Control Development

August 24, 1979

Guest Editorial: Anil Potti Hires “Online Reputation Managers” As Journals Retract His Biomarker Research

April 15, 2011

CAP, ASCCP Recommendations Standardize Lesion Terminology

July 27, 2012

Greenwald Says NCI Still Committed To Year 2000 Goals

January 11, 1991